From April to October, India’s drug exports grew by 8 per cent year on year to USD 15.7 billion versus USD 14.5 billion in the same period last year. “In October, the exports jumped by 29 per cent against 5 per cent growth all along this year and due to this momentum, we are projecting that pharmaceutical exports can clock 28 billion USD in FY24,” the Chairman said
Read MoreReportedly, the extension comes after Lilly's October agreement to acquire Point Biopharma in an all-cash deal valued at USD 1.4 billion, aimed at gaining access to the innovative therapies developed by Point Biopharma for precise cancer targeting
Read MoreThe company has reiterated its margin guidance, targeting a 20 per cent EBITDA margin by Q4FY24 or Q1FY25, coupled with an occupancy goal of 70 per cent
Read MoreNew centres reported a substantial EBITDA growth of 21 per cent year-on-year (23 per cent quarter-on-quarter) to Rs. 122 million
Read MoreThe latest financial report reveals that APHS reported consolidated Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of Rs 6.3 billion, marking a significant 23 per cent quarter-on-quarter increase
Read MoreDr Reddy invested Rs 42.78 lakh, equivalent to 26 per cent of the equity share capital, and an additional Rs 72.84 lakh in compulsorily convertible debentures
Read MoreThe operating EBITDA stood at Rs. 6,732 Mn, indicating an impressive 8.3 per cent increase, with margins reaching 18.8 per cent
Read MoreFortis Healthcare showcased an improvement in net debt to EBITDA, standing at 0.29 compared to 0.44 annually for Q2 FY24 and Q2 FY23
Read More